Shanghai Shyndec Pharmaceutical Co Ltd (600420) - Net Assets

Latest as of June 2026: CN¥15.93 Billion CNY ≈ $2.33 Billion USD

Based on the latest financial reports, Shanghai Shyndec Pharmaceutical Co Ltd (600420) has net assets worth CN¥15.93 Billion CNY (≈ $2.33 Billion USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥19.37 Billion ≈ $2.83 Billion USD) and total liabilities (CN¥3.44 Billion ≈ $503.54 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600420 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥15.93 Billion
% of Total Assets	82.24%
Annual Growth Rate	27.9%
5-Year Change	236.8%
10-Year Change	403.36%
Growth Volatility	75.56

Shanghai Shyndec Pharmaceutical Co Ltd - Net Assets Trend (2001–2025)

This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market cap of Shanghai Shyndec Pharmaceutical Co Ltd.

Annual Net Assets for Shanghai Shyndec Pharmaceutical Co Ltd (2001–2025)

The table below shows the annual net assets of Shanghai Shyndec Pharmaceutical Co Ltd from 2001 to 2025. Also explore Shanghai Shyndec Pharmaceutical Co Ltd (600420) equity growth momentum to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2025-12-31	CN¥34.93 Billion ≈ $5.11 Billion	+127.94%
2024-12-31	CN¥15.32 Billion ≈ $2.24 Billion	+6.86%
2023-12-31	CN¥14.34 Billion ≈ $2.10 Billion	+17.98%
2022-12-31	CN¥12.15 Billion ≈ $1.78 Billion	+17.19%
2021-12-31	CN¥10.37 Billion ≈ $1.52 Billion	+5.61%
2020-12-31	CN¥9.82 Billion ≈ $1.44 Billion	+6.70%
2019-12-31	CN¥9.20 Billion ≈ $1.35 Billion	+9.00%
2018-12-31	CN¥8.44 Billion ≈ $1.24 Billion	+10.40%
2017-12-31	CN¥7.65 Billion ≈ $1.12 Billion	+10.22%
2016-12-31	CN¥6.94 Billion ≈ $1.02 Billion	+330.53%
2015-12-31	CN¥1.61 Billion ≈ $235.83 Million	+15.77%
2014-12-31	CN¥1.39 Billion ≈ $203.72 Million	+5.05%
2013-12-31	CN¥1.33 Billion ≈ $193.92 Million	+11.31%
2012-12-31	CN¥1.19 Billion ≈ $174.21 Million	+25.63%
2011-12-31	CN¥947.63 Million ≈ $138.67 Million	+13.14%
2010-12-31	CN¥837.59 Million ≈ $122.57 Million	+17.40%
2009-12-31	CN¥713.46 Million ≈ $104.40 Million	+12.99%
2008-12-31	CN¥631.47 Million ≈ $92.40 Million	+6.26%
2007-12-31	CN¥594.29 Million ≈ $86.96 Million	+16.19%
2006-12-31	CN¥511.49 Million ≈ $74.85 Million	+6.82%
2005-12-31	CN¥478.84 Million ≈ $70.07 Million	+8.36%
2004-12-31	CN¥441.88 Million ≈ $64.66 Million	+209.01%
2003-12-31	CN¥143.00 Million ≈ $20.92 Million	+24.69%
2002-12-31	CN¥114.68 Million ≈ $16.78 Million	+20.57%
2001-12-31	CN¥95.12 Million ≈ $13.92 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Shanghai Shyndec Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 77767.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥6.75 Billion	42.98%
Other Comprehensive Income	CN¥13.64 Billion	86.88%
Total Equity	CN¥15.70 Billion	100.00%

Shanghai Shyndec Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Shanghai Shyndec Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
GIMV NV BR:GIMB	$1.65 Billion
Gestamp Automocion SA MC:GEST	$1.65 Billion
Ruentex Engineering & Construction Co Ltd TW:2597	$1.65 Billion
EQ Resources Ltd AU:EQR	$1.65 Billion
Der International Home Furnishing Co Ltd SHE:002631	$1.65 Billion
ORG Packaging Co Ltd SHE:002701	$1.65 Billion
Atrium Ljungberg AB (publ) ST:ATRLJ-B	$1.65 Billion
Anterix Inc NASDAQ:ATEX	$1.65 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shanghai Shyndec Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 13,203,924,172 to 15,698,582,000, a change of 2,494,657,828 (18.9%).
Net income of 944,379,815 contributed positively to equity growth.
Dividend payments of 427,895,400 reduced retained earnings.
Other comprehensive income increased equity by 13,188,453,152.
Other factors decreased equity by 11,210,279,739.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥944.38 Million	+6.02%
Dividends Paid	CN¥427.90 Million	-2.73%
Other Comprehensive Income	CN¥13.19 Billion	+84.01%
Other Changes	CN¥-11.21 Billion	-71.41%
Total Change	CN¥-	18.89%

Book Value vs Market Value Analysis

This analysis compares Shanghai Shyndec Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.72x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 61.22x to 0.72x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.14	CN¥8.40	x
2002-12-31	CN¥0.17	CN¥8.40	x
2003-12-31	CN¥0.20	CN¥8.40	x
2004-12-31	CN¥0.70	CN¥8.40	x
2005-12-31	CN¥0.75	CN¥8.40	x
2006-12-31	CN¥0.79	CN¥8.40	x
2007-12-31	CN¥0.91	CN¥8.40	x
2008-12-31	CN¥0.96	CN¥8.40	x
2009-12-31	CN¥1.07	CN¥8.40	x
2010-12-31	CN¥1.26	CN¥8.40	x
2011-12-31	CN¥1.42	CN¥8.40	x
2012-12-31	CN¥1.57	CN¥8.40	x
2013-12-31	CN¥1.73	CN¥8.40	x
2014-12-31	CN¥2.03	CN¥8.40	x
2015-12-31	CN¥1.40	CN¥8.40	x
2016-12-31	CN¥5.14	CN¥8.40	x
2017-12-31	CN¥5.56	CN¥8.40	x
2018-12-31	CN¥6.23	CN¥8.40	x
2019-12-31	CN¥6.59	CN¥8.40	x
2020-12-31	CN¥6.89	CN¥8.40	x
2021-12-31	CN¥7.30	CN¥8.40	x
2022-12-31	CN¥8.91	CN¥8.40	x
2023-12-31	CN¥9.73	CN¥8.40	x
2024-12-31	CN¥9.85	CN¥8.40	x
2025-12-31	CN¥11.70	CN¥8.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shanghai Shyndec Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 6.02%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 10.09%
• Asset Turnover: 0.49x
• Equity Multiplier: 1.22x
Recent ROE (6.02%) is below the historical average (13.11%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	18.46%	9.78%	0.85x	2.23x	CN¥6.68 Million
2002	22.88%	9.62%	1.12x	2.13x	CN¥12.33 Million
2003	20.53%	6.12%	1.46x	2.30x	CN¥12.02 Million
2004	9.17%	10.27%	0.69x	1.29x	CN¥-3.33 Million
2005	13.61%	11.67%	0.86x	1.36x	CN¥15.57 Million
2006	11.22%	9.32%	0.91x	1.32x	CN¥5.54 Million
2007	17.95%	15.06%	0.87x	1.36x	CN¥41.66 Million
2008	9.78%	7.95%	0.85x	1.44x	CN¥-1.23 Million
2009	14.47%	7.65%	1.25x	1.51x	CN¥27.51 Million
2010	14.94%	7.60%	1.25x	1.57x	CN¥35.76 Million
2011	14.73%	7.05%	1.14x	1.83x	CN¥38.55 Million
2012	14.15%	5.81%	0.89x	2.73x	CN¥37.50 Million
2013	13.34%	5.65%	0.75x	3.16x	CN¥33.27 Million
2014	16.28%	6.91%	0.72x	3.26x	CN¥73.28 Million
2015	39.90%	5.90%	2.17x	3.11x	CN¥397.15 Million
2016	8.36%	5.23%	0.61x	2.63x	CN¥-93.46 Million
2017	8.36%	6.06%	0.56x	2.46x	CN¥-101.54 Million
2018	10.37%	6.23%	0.69x	2.42x	CN¥24.90 Million
2019	8.65%	5.38%	0.69x	2.32x	CN¥-102.38 Million
2020	7.98%	5.17%	0.69x	2.24x	CN¥-164.33 Million
2021	6.61%	4.08%	0.73x	2.22x	CN¥-291.00 Million
2022	6.09%	4.84%	0.66x	1.90x	CN¥-402.75 Million
2023	5.58%	5.73%	0.62x	1.56x	CN¥-546.96 Million
2024	8.21%	9.91%	0.55x	1.51x	CN¥-236.77 Million
2025	6.02%	10.09%	0.49x	1.22x	CN¥-625.48 Million

Industry Comparison

This section compares Shanghai Shyndec Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,877,324,223
Average return on equity (ROE) among peers: 8.08%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Shanghai Shyndec Pharmaceutical Co Ltd (600420)	CN¥15.93 Billion	18.46%	0.22x	$1.65 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.78 Billion	1.33%	4.40x	$589.07 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.56 Billion	7.90%	1.45x	$422.95 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$2.46 Billion	15.95%	0.27x	$4.31 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.17 Billion	10.59%	0.88x	$2.30 Billion
Wedge Industrial Co Ltd (000534)	$1.41 Billion	5.42%	0.68x	$1.73 Billion
Yunnan Baiyao Group Co Ltd (000538)	$32.60 Million	12.25%	0.82x	$13.40 Billion
Hainan Haiyao Co Ltd (000566)	$2.54 Billion	7.70%	0.92x	$945.43 Million
Tus Pharmaceutical Group Co Ltd (000590)	$380.02 Million	7.98%	0.67x	$320.64 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$3.92 Billion	4.44%	2.20x	$1.01 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$23.53 Billion	7.26%	0.16x	$3.11 Billion

About Shanghai Shyndec Pharmaceutical Co Ltd

SHG:600420 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.65 Billion

CN¥11.27 Billion CNY

Market Cap Rank

#6942 Global

#1469 in China

Share Price

CN¥8.40

Change (1 day)

+0.36%

52-Week Range

CN¥7.78 - CN¥10.97

All Time High

CN¥17.27